CEREBROPROTECTIVE ACTIVITY OF NEW DERIVATIVES OF PIRIMIDINE4 1H ONE PIR9 AND PIR10 IN IRREVERSIBLE OCCLUSION OF THE COMMON CAROTID ARTERY

The frequency of cerebral hemodynamics disorders remains one of the most relevant problems in the modern world. Disorders of brain blood supply lead to high disability of the population, director disability, as well as fatal outcomes. There is an extensive group of drugs that contribute to the treatment and prevention of cerebrovascular disorders, however, they do not fully meet the requirements of practitioners. In this regard, the task of purposeful search and study of new substances with anti-ischemic activity becomes a task of experimental pharmacology. The aim of this work is to study the cerebroprotective activity of the new derivatives of Pirimidine-4-(1H)-OHA PIR-9 and PIR-10 in irreversible occlusion of the common carotid artery. Materials and methods. The study was carried out on 120 male rats of the Wistar line, weighing 200-220 g, divided into 6 equal groups. The investigated substances - PIR-9 and PIR-10 (50 mg / kg), vinpocetine (3.2 mg / kg), cinnarizine (5.6 mg / kg), a suspension of puri ed water with Tween-80 – were injected intraperitoneally for 10 days , as well as an hour before the operation. Global cerebral ischemia was modeled under chloral hydrate anesthesia (350 mg / kg) by dressing the common carotid arteries. 24 hours after the ischemia model, the survival, behavioral activity, cognitive and mnestic functions as well as certain metabolic disorders were evaluated. Results and discussion. In the experimental study of cerebroprotective action of the compounds PIR-9 and PIR-10 (derivatives of pyrimidine-4-(1H)-OHA) a decrease in neurological, locomotor, tentative research, cognitive, mental disorders in the background of ligation of common carotid artery was established. In addition, after preventive administration of the studied substances PIR-9 and PIR-10, there was an improvement in the processes of energy metabolism in the postischemic period. Conclusion. As for the cerebroprotective activity, the experimental substances (PIR-and PIR 9-10) were superior to the reference preparation of Vinpocetine and were comparable with Cinnarizine. That proves the feasibility of further study of derivatives of pyrimidine-4(1H)-ONA as potential anti-ischemic agents.

1. Mazina NV, Volotova EV, Kurkin DV. Nejroprotektornoe dejstvie novogo proizvodnogo GAMK-RGPU-195 pri ishemii golovnogo mozga [Neuroprotective effect of a new derivative of GABA-RGPU-195 in cerebral ischemia]. Fundamental research. 2013;6(Pt 6):1473-6. Russian.

2. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, De Sarro G. Cerebral stroke injury: the role of cytokines and brain in ammation. Journal of Basic and Clinical Physiology and Pharmacology. 2014 May 1;25(2):131-7. DOI: 10.1515/jbcpp-2013-0121

3. Jin R, Liu L, Zhang S, Nanda A, Li G. Role of in ammation and its mediators in acute ischemic stroke. Journal of Cardiovascular Translational Research. 2013 October;6(5):834–51. DOI: 10.1007/s12265-013-9508-6

4. Jin R, Yang G, Li G. In ammatory mechanisms in ischemic stroke: role of in ammatory cells // Journal of Leukocyte Biology. 2010 May;87(5):779-89. DOI: 10.1189/jlb.1109766

5. Gusev EI, Skvorzova VI. Ishemiya golovnogo mozga [Ischemia of the brain]. Moskva: Medicina; 2001. 328 p. Russian.

6. Tyurenkov IN, Kurkin DV, Volotova EV, Litvinov AA, Bakulin DA. Vliyanie razlichnyh kompozicij fenibuta s organicheskimi kislotami na nevrologicheskij, kognitivnyj i povedencheskij de cit u krys pri fokal’noj ishemii golovnogo mozga [Effect of organic acid compositions of phenibut on neurological, cognitive and behavioral de cit in rats with focal ischemic brain damage]. Siberian Medical Journal (Irkutsk). 2012;115(8):61-3. Russian.

7. Soultanov VS, Zarubina IV, Shabanov PD. Cerebroprotektornye i energostabiliziruyushchie effekty poliprenol’nogo preparata roprena pri ishemii golovnogo mozga u krys [Cerebroprotective and energy stabilizing effects of polyprenol drug ropren in ischemia of the brain in rats]. Reviews on clinical pharmacology and drug therapy. 2010;8(3):31-47. Russian.

8. Kodonidi IP. Molekulyarnoe konstruirovanie N-zameshchennyh proizvodnyh 1,3-diazinona-4 [Molecular design of n-substituted 1,3-diazinone-4 derivatives]. Pharmacy. 2010;1:36-40. Russian.

9. Samotrueva MA, Tsibizova AA, Yasenyavskaya AL, Ozerov AA, Tyurenkov IN. Farmakologicheskaya aktivnost’ proizvodnyh pirimidinov [Pharmacological activity of pyrimidine derivatives]. Astrakhan Medical Journal. 2015;10(1):12-29. Russian.

10. Gupta JK, Chaudhary A, Dudhe R, Varuna K, Sharma PK, Verma PK. A review on the synthesis and therapeutic potential of pyrimidine derivatives. International journal of pharmaceutical sciences and research. 2010. No. 1. P. 34–49. DOI: 10.13040/IJPSR.0975-8232.1(5).34-49

11. Palmer RA, Potter BS, Leach MJ, Chowdhry BZ. X-ray Crystallographic Structures of Neuroprotective Pyrimidine Derivatives: (I) the Mesylate Salt of BW1003C87 and (II) Sipatrigine Base. Journal of Chemical Crystallography. 2007;37:771-7. DOI: 10.1007/s10870-007-9248-z

12. Caputi L, Hainsworth AH, Lavaroni F, Leach MJ, McNaughton NC, Mercuri NB, Randall AD, Spadoni F, Swan JH, Stefani A. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. Brain Research. 2001 Nov 01;919(2):259-68. DOI: 10.1016/S0006-8993(01)03029-3

13. Stefani A, Hainsworth AH, Spadoni F, Bernardi G. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br J Pharmacol. 1998;125(5):1058–64. DOI: 10.1038/ sj.bjp.0702134

14. Hainsworth AH, Stefani A, Calabresi P, Smith TW, Leach MJ. Sipatrigine (BW 619C89) is a Neuroprotective Agent and a Sodium Channel and Calcium Channel Inhibitor. CNS Drug Reviews. 2000;6(2):111-34. DOI: 10.1111/j.1527-3458.2000.tb00141.x

15. Soares P, Costa R, Froufe HJC, Calhelha RC, Peixoto D, Ferreira ICFR, Abreu RMV, Soares R, Queiroz MJRP. 1-Aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modelling Studies. BioMed Research International. 2013;2013. 9 p. DOI: 10.1155/2013/154856

16. Petrova EV, Oganesyan ET, Kodonidi IP, ZHoglo EN. Cravnitel’naya antioksidantnaya i antigipoksicheskaya aktivnost’ novogo proizvodnogo 1,4-digidro-4-oksopirimidina — soedineniya PDMPT •HCL i meksidola [Comparative antioxidant and antihypoxic activities of new 1,4-dihydro-4-oxopyrimidine derivative - compound PDMpT HCl and Mexidol]. Experimental and Clinical Pharmacology. 2013;76(6):38-40. DOI: 10.30906/0869-2092-2013-76-6-38-40. Russian.

17. Voronkov AV, Kodonidi IP, Mamleev AV, Sochnev VS, Glushko AA. Poisk i izuchenie endotelioprotektornoj aktivnosti novyh 2-stirilproizvodnyh pirimidin-4(1N)-ona na fone modelirovaniya nedostatochnosti polovyh gormonov [Search and study of new activity endothelioprotectors 2-steril derivatives pyrimidin-4 (1H) – one on background modeling sex hormone de ciency]. Modern problems of science and education [Internet]. 2015;5 [cited 2017 Jan 24]. Available from: http://www.scienceeducation.ru/ru/article/view?id=22482. Russian.

18. Granik VG, Kaminka ME, Grigor’ev NB, Severina IS, Kalinkina MA, Makarov VA, Levina VI. Furoksanopirimidiny kak ekzogennye donory oksida azota [Furoxanopyrimidines as exogenous nitric oxide donors]. Pharmaceutical Chemistry Journal. 2002;36(10):7-11. Russian.

19. Voronkov AV, Glushko AA. Novaya matematicheskaya model’ dlya prognozirovaniya endotelioprotektornoj aktivnosti veshchestv na osnove molekulyarnogo dokinga [A novel molecular docking based mathematical model for endothelial-protective activity of substances prediction]. Problems of biological, medical and pharmaceutical chemistry. 2013;3:42-7. Russian.

20. Voronkov AV, Mamleev AV, Pozdnyacov DI. Izuchenie vliyaniya stirilproizvodnyh pirimidin–4(1n)-ona na sostoyanie antitromboticheskogo potenciala, na fone eksperimental’no vyzvannoj nedostatochnosti polovyh gormonov [Study of in uence derivatives of 2-stiril pyrimidine-4(1h)-one to state ‎antithrombotic potential, against experimentally induced insuf ciency of sex ‎hormones]. The journal of scienti c articles «Health and Education Millennium». 2016;18(2):603-8. Russian.

21. Tyurenkov IN, Kurkin DV, Bakulin DA, Volotova EV, SHafeev MA. Gipolipidemicheskoe, antioksidantnoe i endoteliopozitivnoe dejstvie novogo agonista receptora GPR 119 soedineniya ZB-16 pri eksperimental’nom saharnom diabete [Hypolipidemic, Antioxidant, and Endothelial Protective Effect of Compound ZB-16 (Novel GPR119 Receptor Agonist) in Rats with Experimental Type 2 Diabetes]. Experimental and Clinical Pharmacology. 2017;80(1):18-23. Russian.

22. Panda SS, Chowdary PV. Synthesis of Novel Indolyl-Pyrimidine Antiin ammatory, Antioxidant and Antibacterial Agents. Indian J. of Pharm. Sciences. 2008 Mar-Apr;70(2):208-15. DOI: 10.4103/0250-474X.41457

23. El-Mekabaty A. Synthesis and Antioxidant Activity of Some New Heterocycles Incorporating the Pyrazolo-[3,4-D] Pyrimidin-4-One Moiety. Chemistry of Heterocyclic Compounds 2015;50(12):1698-706. DOI: 10.1007/s10593-015-1640-6

24. El-Mekabaty A, Habib OMO, Moawad EB, Hasel AM. Synthesis and Antioxidant Activity of New Pyrazolo[1,5-a] Pyrimidine Derivatives Incorporating a Thiazol-2-yldiazenyl Moiety. Journal of Heterocyclic Chemistry. 2015 Sep 1;53(6):1820-6. DOI: 10.1002/jhet.2492

25. Lugovoj IS, Kodonidi IP, Voronkov AV, SHabanova NB, Kodonidi MI. Celenapravlennyj sintez n-peptidnyh proizvodnyh pirimidin-4(1n)-ona, obladayushchih cerebroprotektornymi svojstvami [Targeted synthesis of n-peptide derivatives of pyrimidine-4 (1H) -one, which possess cerebroprotective properties]. The journal of scienti c articles «Health and Education Millennium». 2017;19(8):195-9. Russian.

26. Voronkov AV, Shabanova NB, Pozdnyakov DI, Lugovoy IS, Kodonidi IP. Vliyanie novyh proizvodnyh pirimi-din-4(1n)-ona na psihoemocional’nyj disbalans i nekotorye narusheniya energeticheskogo obmena u krys na fone ishemii golovnogo mozga [In uence of new derivative pirimidin-4(1h)-she on psychoemotional imbalance and some violations of power exchange at rats against the background of brain ischemia]. Modern problems of science and education [Internet]. 2017;5 [cited 2018 Jan 21]. Available from: https://science-education.ru/ru/article/ view?id=26738. Russian.

27. Nazarova LYe, D’yakova IN. Vliyanie kisloty ferulovoj na zonu nekroza, voznikayushchego v rezul’tate okklyuzii srednej mozgovoj arterii [Effects of ferulic acid on the necrosis area caused by the middle cerebral artery occlusion]. Bashkortostan Medical Journal. 2011;3:133-5. Russian.

28. Gannushkina IV. Mozgovoe krovoobrashchenie pri raznyh vidah cirkulyatornoj gipoksii mozga [Cerebral circulation at different types of circulatory hypoxia of the brain]. Annals of the Russian academy of medical sciences. 2000;9:22-7. Russian.

29. Mironov AN. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv [A guide to pre-clinical drug research]. Chast’ pervaya. Mockva: Grif i K; 2012. 944 p. Russian.

30. Mitrohin NM, Turyanskij EE, Makarova LM, Pogorelyj VE, Skachilova SYa. Vliyanie vinpocetina pri terapii s kombinaciej antigipertenzivnyh sredstv na metabolizm mozga zhivotnyh s arterial’noj gipertenziej i gipertenziej, oslozhnennoj ishemiej mozga [The effect of vinpocetine on therapy with a combination of antihypertensive agents on brain metabolism in animals with arterial hypertension and hypertension complicated by brain ischemia]. Belgorod State University Scienti c Bulletin. 2014;26(11-1):98-103. Russian.